Author Archives: admin


Stem Cell Clinic > Articles by: admin

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

By Global News Feed

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy to prevent blindness in patients with Stargardt disease, during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Read the original:
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

By Global News Feed

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor Relations team at ir@glpg.com.

Original post:
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

By Global News Feed

BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.

See the article here:
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

By Global News Feed

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT.

The rest is here:
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

By Global News Feed

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression

The rest is here:
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

By Global News Feed

NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements.

See the original post:
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

By Global News Feed

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.

Continue reading here:
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

→←